Raymond James Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Raymond James Financial’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.7M	Buy	331,373 +120,075	+57%	+$7M	0.01%	1519
2025 Q4	$12.6M	Buy	211,298 +119,692	+131%	+$6.52M	﹤0.01%	1785
2025 Q3	$4.96M	Buy	91,606 +19,924	+28%	+$1.14M	﹤0.01%	2455
2025 Q2	$3.94M	Sell	71,682 -26,651	-27%	-$1.57M	﹤0.01%	2540
2025 Q1	$6.95M	Buy	98,333 +16,519	+20%	+$1.11M	﹤0.01%	2083
2024 Q4	$5.38M	Buy	+81,814	New	+$5.48M	﹤0.01%	2284

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's BMRN Position: Q1 2026 in Review

Raymond James Financial increased its BioMarin Pharmaceuticals (BMRN) stake by 57% in Q1 2026, buying an estimated $7M and bringing the position to 331,373 shares worth $18.7M. The position accounts for 0.01% of the portfolio, ranked #1519.

Raymond James Financial first reported a position in BMRN in Q4 2024 and has held it in 6 quarters since. 556 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Raymond James Financial held 331,373 shares of BioMarin Pharmaceuticals worth $18.7M as of Q1 2026.
Raymond James Financial bought 120,075 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $7M.
BioMarin Pharmaceuticals made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1519 holding.
Raymond James Financial first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.